- Trial phase
- Phase 3
- Time to market
- Uncertain for Sjögren's, submission status unclear as of Oct 2026; if filed, potential FDA decision in H2 2027. ITP submission planned for 2027 pending VAYHIT1 data. SLE likely 2028 or later.
- Why 4/10
- No confirmed dated binary catalyst in the next ~12 months: the Sjögren's regulatory submission status is uncertain (originally planned for Q3 2026 but not confirmed as filed), and the ITP submission is planned for 2027 without a specific date. Ianalumab is one of many pipeline assets at a large-cap pharma (Novartis), limiting single-drug share-price impact.
Watch for any Novartis announcement confirming the Sjögren's regulatory submission, if filed, a PDUFA date would likely land in H2 2027. Also monitor VAYHIT1 topline data (first-line ITP), which could trigger the ITP regulatory submission in 2027. The NEJM publication and mixed efficacy signal may increase regulatory uncertainty.
Price Chart
Executive Summary
Ianalumab (VAY736) is Novartis' investigational anti-BAFF-R monoclonal antibody being developed primarily for Sjögren's disease, with additional programs in immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE). Two Phase 3 trials in Sjögren's (NEPTUNUS-1 and -2) met their primary endpoint of reduced disease activity, but the modest effect size and lack of clear benefit on patient-reported symptoms, published in NEJM on October 22, 2026, have raised questions about the regulatory path. The FDA granted Breakthrough Therapy designation in January 2026, but the planned global submission (originally early 2026, then pushed to Q3 2026) has not been confirmed as filed. A new Phase 3 trial (THALASSA) targeting high-symptom-burden patients started in July 2026. In ITP, the VAYHIT2 trial was positive, and Novartis plans to submit for FDA approval in 2027 pending VAYHIT1 data. For a large-cap pharma like Novartis, ianalumab is one of many pipeline assets, so any single-catalyst impact is limited.
How It Works
Ianalumab is a lab-engineered antibody that targets and blocks BAFF-R, a protein on the surface of B-cells (a type of immune cell). It works through a dual mechanism: it directly kills B-cells and also blocks signals that keep B-cells alive and active. Since overactive B-cells drive autoimmune diseases like Sjögren's, ITP, and lupus, reducing their activity can dampen the misguided immune attack.
Trial Status
Two Phase 3 trials in Sjögren's disease (NEPTUNUS-1, NEPTUNUS-2) completed and published in NEJM (Oct 2026), met primary endpoint with modest effect. A third Phase 3 trial in Sjögren's (THALASSA, high-symptom-burden patients) began July 2026. In ITP, Phase 3 VAYHIT2 met its primary endpoint (Aug 2025, published NEJM Apr 2026); VAYHIT1 (first-line ITP) is ongoing. Two Phase 3 SLE trials (SIRIUS-SLE 1 and 2) are ongoing/recruiting.
The Two-Sided Case
Upcoming Catalysts
- Confirmation of Sjögren's regulatory submission (status unclear as of Oct 2026)
- VAYHIT1 (first-line ITP) Phase 3 topline data, expected 2026/2027
- Potential PDUFA date if Sjögren's BLA is filed
- SIRIUS-SLE Phase 3 readouts (timeline unknown)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report